Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flow from operating activities:
Net income	$ 1,292.9	$ 1,632.2	$ 1,161.5
Adjustments to reconcile net income to net cash flow from operating activities:
Depreciation and amortization	779.9	673.2	494.8
Impairment of intangible assets	7.9	60.2	0.0
Impairment of ROU asset	52.9	0.0	0.0
Excess and obsolescence charges related to inventory	29.2	101.9	124.4
Amortization of acquired inventory step-up	240.8	230.0	31.5
Acquired in-process research and development	85.0	0.0	0.0
Share-based compensation	290.8	291.2	264.2
Contingent consideration	33.6	27.7	0.0
Deferred income taxes	361.6	(158.1)	(305.8)
(Gain) loss on strategic investments	19.3	101.4	277.1
Gain on sale of priority review voucher, net	0.0	(88.6)	0.0
Other	68.3	159.6	148.2
Changes in operating assets and liabilities, net of effects of business acquired:
Accounts receivable	102.7	222.3	61.3
Due from anti-CD20 therapeutic programs	(60.6)	(28.1)	(4.6)
Inventory	(64.7)	(273.8)	(130.9)
Accrued expense and other current liabilities	171.1	24.6	(201.6)
Income tax assets and liabilities	(958.1)	78.5	(299.0)
Other changes in operating assets and liabilities, net	(248.0)	(178.7)	(73.9)
Net cash flow provided by (used in) operating activities	2,204.6	2,875.5	1,547.2
Cash flow from investing activities:
Purchases of property, plant and equipment	(153.8)	(153.7)	(277.0)
Proceeds from sales and maturities of marketable securities	23.0	0.0	7,380.8
Purchases of marketable securities	(1,258.3)	0.0	(5,140.7)
Proceeds from sale of equity interest in Samsung Bioepis	0.0	406.8	788.1
Proceeds from sale of priority review voucher, net	0.0	88.6	0.0
Acquired in-process research and development	(50.0)	0.0	0.0
Acquisitions of intangible assets	(31.6)	(206.1)	(34.4)
Proceeds from sales of strategic investments	56.7	144.7	119.6
Other	42.9	(4.7)	(11.3)
Net cash flow provided by (used in) investing activities	(1,371.1)	(799.2)	(4,101.0)
Cash flow from financing activities:
Payments related to issuance of stock for share-based compensation arrangements, net	(10.0)	(31.3)	(44.3)
Proceeds from borrowings	1,733.1	0.0	997.2
Repayments of borrowings	(1,750.0)	(650.0)	(809.9)
Net (distribution) contribution to noncontrolling interest	0.0	0.0	12.3
Contingent consideration payments	(280.0)	0.0	0.0
Other	5.0	(2.2)	(6.0)
Net cash flow provided by (used in) financing activities	(301.9)	(683.5)	149.3
Net increase (decrease) in cash and cash equivalents	531.6	1,392.8	(2,404.5)
Effect of exchange rate changes on cash and cash equivalents	101.9	(67.7)	35.1
Cash and cash equivalents, beginning of the year	2,375.0	1,049.9	3,419.3
Cash and cash equivalents, end of the year	3,008.5	2,375.0	1,049.9
Reata Pharmaceuticals, Inc
Cash flow from investing activities:
Acquisition, net of cash acquired	0.0	0.0	(6,926.1)
Hi-Bio Acquisition
Cash flow from investing activities:
Acquisition, net of cash acquired	$ 0.0	$ (1,074.8)	$ 0.0